SPAA's Andrea Slattery points to biotechnology opportunities

SPAA self-managed super funds SMSFs smsf trustees chief executive officer

5 November 2012
| By Staff |
image
image
expand image

With the right positioning and education, biotechnology and life sciences companies could present alternative investment opportunities for self-managed super funds (SMSFs), according to Andrea Slattery, chief executive officer of the SMS Professionals' Association of Australia (SPAA).

"SMSFs understand risk and returns and are generally well educated, with close to 75 per cent having at least an undergraduate degree or equivalent," she said.

"This, added to the opportunity to invest in ethical, potentially life-saving products may make the life sciences a possible option for SMSF trustees to consider.

"However more must be done by the sector to create more accessible points for investing which provide long-term value," Slattery said.

According to AusBiotech, whose conference Slattery will speak at later this month, investment by institutional super funds in Australian venture capital, often the biggest supporter of biotechnology and life sciences companies, has fallen recently.

And with a similar drop-off in investment by the Australian Federal Government set to take place from early 2013, the reality is that biotechnology and life sciences companies may need to search for other sources of investment.

"Biotechnology and life sciences companies should, in most cases, be seen as a long-term investment," said Slattery. "SMSFs understand this and have the ability to and often [do] take a longer term-view.

"SMSFs do not have adequacy, longevity or sustainability problems; they are able to be flexible and invest where they want to, and don't have liquidity problems in achieving this generally, and they are able to understand and invest in long-term investments while understanding the risk return relationship."

However, Slattery identified three core elements that life sciences needed to work on to engage SMSFs in education, access and commercialisation.

"From an information point-of-view, life science organisations need to put the time into education, both of trustees and financial advisors," she said.

"This, along with well-developed commercialisation arrangements and creating entry points that are not out of reach for SMSFs, will create more opportunities for the sector."

Read more about:

AUTHOR

Recommended for you

sub-bgsidebar subscription

Never miss the latest news and developments in wealth management industry

MARKET INSIGHTS

GG

So shareholders lose a dividend plus have seen the erosion of value. Qantas decides to clawback remuneration from Alan ...

4 weeks ago
Denise Baker

This is why I left my last position. There was no interest in giving the client quality time, it was all about bumping ...

4 weeks 1 day ago
gonski

So the Hayne Royal Commission has left us with this. What a sad day for the financial planning industry. Clearly most ...

4 weeks 1 day ago

The decision whether to proceed with a $100 million settlement for members of the buyer of last resort class action against AMP has been decided in the Federal Court....

2 weeks ago

A former Brisbane financial adviser has been found guilty of 28 counts of fraud where his clients lost $5.9 million....

4 weeks ago

The Financial Advice Association Australia has addressed “pretty disturbing” instances where its financial adviser members have allegedly experienced “bullying” by produc...

3 weeks 1 day ago

TOP PERFORMING FUNDS